As such, these studies provide a new understanding of LAIR-1 biology, and a novel therapeutic approach, to the best of our knowledge, to treat AML by targeting LAIR-1 with an agonist mAb. This evidence concerns the gene LAIR1 and acute myeloid leukemia.